TABLE 2.
Demographics, baseline characteristics, and immunosuppressive treatments of control and prophylactic eculizumab treatment cohorts
| Control cohort | Prophylactic treatment cohort | |
|---|---|---|
| Kidney transplants | 33 | 38 |
| Transplant recipients | 32 | 38 |
| Demographics | ||
| Mean age in y at transplantation (SD) | 28.3 (±15.6)** | 38.7 (±13.6) |
| Children (<16 y old) (% of those with available data) | 9 (27.3) | 3 (7.9) |
| Female recipients (% of transplants) | 25 (75.8) | 25 (65.8) |
| Median y of transplantation (range) | 2007 (2002-2016) *** | 2015 (2013-2017) |
| Recipient complement defect status (% of transplants) | ||
| Nil | 0 | 6 (15.7) |
| VUS | 10 (30.3) | 6 (15.7) |
| Pathological variant | 21 (63.6) | 24 (63.2) |
| Complement factor B | 0 | 0 |
| Complement factor H (CFH) | 17 (51.5) | 16 (42.1) |
| Complement factor I (CFI) | 2 (6.1) | 0 |
| CFH + CFI | 0 | 1 (2.6) |
| C3 | 2 (6.1) | 7 (18.4) |
| Number tested for anti-FH | 28 (87.5) | 32 (84.2) |
| Isolated anti-FH detected | 2 | 2 |
| Anti-FH detected with genetic variant | 5 | 1 |
| Risk of aHUS recurrence | ||
| Medium | 14 (42.4) | 12 (31.6) |
| High | 19 (57.6) | 26 (68.4) |
| Transplant details | ||
| First transplants (%) | 26 (78.8) | 24 (63) |
| Live donor transplants (% of n) | n = 2210 (45.5) | n = 388 (21) |
| Median HLA mismatch (range) | not available | 3 (0-6)n = 33 |
| Plasma exchange | ||
| Received posttransplant PLEX | 7***(n = 11 with available data) | 1 |
| Immunosuppression | ||
| Available data on induction immunosuppression | not available | n = 23 |
| Basilixumab | 19 | |
| Antithymocyte globulin | 4 | |
| Alemtuzumab | 0 | |
| Available data on maintenance immunosuppression | not available | n = 33 |
| Tacrolimus + Mycophenolate mofetil + Prednisolone | 28 | |
| Tacrolimus + Mycophenolate mofetil | 1 | |
| Ciclosporin + Mycophenolate mofetil | 0 | |
| Tacrolimus + Prednisolone | 2 | |
| Tacrolimus + Azathioprine + Prednisolone | 2 | |
| Meningococcal vaccine received before first D of eculizumab treatment | ||
| ACWY serotype (n gives those with available data) | not applicable | 32 (n = 33) |
| B serotype (n gives those with available data) | not applicable | 26 (n = 32) |
Data for kidney transplants received since 2002 at medium or high risk of recurrence of atypical hemolytic uremic syndrome (aHUS) who were not treated with eculizumab (control cohort) and kidney transplants treated with prophylactic eculizumab at the time of transplantation (prophylactic treatment cohort). No recipients had identified pathological variants in noncomplement pathway gene associated with aHUS. Whenever data are not available for complete group, number with available data is given (n).
anti-FH, factor H autoantibody; PLEX, plasma exchange; VUS, variant of uncertain significance.
*P < 0.05,
P < 0.01,
P < 0.001 for difference compared with prophylactic treatment group.